Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation
MetadataShow full item record
CitationCingozbay, B. Y., Yiginer, O., Cebeci, B. S., Kardesoglu, E., Demiralp, E. ve Dincturk, M. (2002). Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrilation. Blood coagulation & fibrinolysis, Wolters Kluwer Health. 13(7), s. 609–613.
Thromboembolism is the most important complication in patients with atrial fibrilation (AF). Homocysteine is a toxic amino acid that has been recently accepted as a risk factor for atherosclerosis and stroke. The aim of the present study is to show whether there is a relation between hyperhomocysteinemia and thromboembolic complications in patients with non-valvular AF. We admitted 38 patients with non-valvular AF. The patients were divided into two groups: group A (n = 20; mean age, 75.7 +/- 10.4 years; three males/17 females), and group B (n = 18; mean age, 68.0 +/- 10.6 years; 11 males/seven females). While group A consisted of the patients with AF and stroke, group B was composed of the patients with AF but without stroke. The patients having sinus rhythm (15 subjects) were used as the reference group to obtain the cut-off value. Homocysteine was measured by the immunoassay method. The means of the homocysteine levels were 12.4 +/- 3.3 micromol/l in group A, 8.3 +/- 2.3 micromol/l in group B and 9.3 +/- 1.8 micromol/l in the reference group. The cut-off value was 10.6 micromol/l. Group A had a statistically higher homocysteine level than not only group B, but also the reference group (P < 0.05). While 60% of group A (n = 12) had the elevated homocysteine level, the rate was only 22% for group B (n = 4). In conclusion, hyperhomocysteinemia may be one of the explanations for the increased rate of thromboembolic complications in older patients with AF.
SourceBlood Coagulation & Fibrinolysis
- Makale Koleksiyonu 
The following license files are associated with this item: